A recent study has found that Saxenda, a weight-loss drug made by Novo Nordisk, poses risks to bone health and bone density. The research indicates that similar risks apply to newer treatments like Ozempic and Wegovy. These findings come amid a global demand for weight-loss drugs, leading to shortages and the emergence of counterfeit versions. The European Union has urged a crackdown on the cosmetic misuse of Ozempic to address the worsening drug shortages for diabetics. The stocks $NVO and $LLY are notably affected.
$NVO Weight-Loss Drug Saxenda Poses Risk to Bone Health, Study Finds https://t.co/XBoseRq4ve
EU urges clampdown on cosmetic misuse of Novo's Ozempic amid worsening drug shortages for diabetics. https://t.co/lIFVswRPyu
$NVO $LLY EU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics https://t.co/hZZlEvuvPD
Fake versions of Ozempic, the injectable diabetes drug many use for weight loss, are springing up around the world. https://t.co/XnTbrquYmo
With everyone from obesity patients to celebrities demanding Ozempic and other drugs like it, the frenzy has sparked global shortages—opening the door to life-threatening fakes. https://t.co/ayBsjfOEDv
Weight Loss Drugs Like Ozempic Could Reduce Bone Density, Study Suggests https://t.co/4iyJokUnna https://t.co/tqupoyxGq4
Saxenda, an older daily weight-loss shot made by Novo Nordisk that’s similar to newer treatments like Ozempic, poses a risk to bone health, according to a study https://t.co/eQ6SN8RLiP
NOVO DRUG SAXENDA INCREASES BONE HEALTH RISKS, STUDY FINDS RESEARCHER SAYS BONE HEALTH RISKS ALSO APPLY TO OZEMPIC, WEGOVY $NVO $LLY